Published in J Nucl Med on November 15, 2010
Prospective of ⁶⁸Ga-radiopharmaceutical development. Theranostics (2013) 1.32
PET imaging of inflammation biomarkers. Theranostics (2013) 1.04
18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials. Eur J Nucl Med Mol Imaging (2011) 0.94
Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patients. Eur J Nucl Med Mol Imaging (2013) 0.92
Gallium-labelled peptides for imaging of inflammation. Eur J Nucl Med Mol Imaging (2012) 0.91
The importance of correction for tissue fraction effects in lung PET: preliminary findings. Eur J Nucl Med Mol Imaging (2011) 0.85
Improved In vivo Assessment of Pulmonary Fibrosis in Mice using X-Ray Dark-Field Radiography. Sci Rep (2015) 0.79
Noninvasive imaging of experimental lung fibrosis. Am J Respir Cell Mol Biol (2015) 0.77
Imaging Pulmonary Inflammation. J Nucl Med (2016) 0.76
68Ga-DOTATATE PET/CT imaging of indeterminate pulmonary nodules and lung cancer. PLoS One (2017) 0.75
Matrix metalloproteinase-targeted imaging of lung inflammation and remodeling. J Nucl Med (2016) 0.75
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J (2014) 6.32
Extracorporeal Co2 removal in hypercapnic patients at risk of noninvasive ventilation failure: a matched cohort study with historical control. Crit Care Med (2015) 5.22
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood (2011) 2.74
MSCT multi-criteria: a novel approach in assessment of mediastinal lymph node metastases in non-small cell lung cancer. Eur J Radiol (2010) 2.07
Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med (2009) 1.87
Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging (2010) 1.85
Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging (2007) 1.81
Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun (2007) 1.72
Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol (2009) 1.69
Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging (2010) 1.68
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol (2008) 1.64
Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology (2007) 1.61
The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol (2010) 1.61
2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed) (2016) 1.61
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica (2007) 1.59
Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging (2011) 1.53
18F-FDG PET/CT impact on testicular tumours clinical management. Eur J Nucl Med Mol Imaging (2013) 1.49
18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. Leuk Lymphoma (2006) 1.48
Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol Imaging (2011) 1.46
The Senile Lung as a Possible Source of Pitfalls on Chest Ultrasonography and Computed Tomography. Respiration (2015) 1.46
Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med (2005) 1.46
(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. Eur J Nucl Med Mol Imaging (2012) 1.44
The clinical use of PET with (11)C-acetate. Am J Nucl Med Mol Imaging (2011) 1.43
Unenhanced MDCT findings of acute bowel ischemia. AJR Am J Roentgenol (2008) 1.42
Multicenter study evaluating extraprostatic uptake of 11C-choline, 18F-methylcholine, and 18F-ethylcholine in male patients: physiological distribution, statistical differences, imaging pearls, and normal variants. Nucl Med Commun (2015) 1.39
Different tracheotomy tube diameters influence diaphragmatic effort and indices of weanability in difficult to wean patients. Respir Care (2012) 1.39
Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging (2010) 1.39
CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab (2010) 1.33
Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results. Eur J Nucl Med Mol Imaging (2013) 1.26
Airway malacia in chronic obstructive pulmonary disease: prevalence, morphology and relationship with emphysema, bronchiectasis and bronchial wall thickening. Eur Radiol (2009) 1.25
Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma. Clin Cancer Res (2007) 1.25
Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging (2011) 1.19
68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med (2010) 1.19
Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies. Nucl Med Commun (2007) 1.19
(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging (2015) 1.18
Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging (2011) 1.17
Radiopeptide imaging and therapy in Europe. J Nucl Med (2011) 1.16
Imaging of a small bowel cavernous hemangioma: report of a case with emphasis on the use of computed tomography and enteroclysis. Acta Biomed (2007) 1.13
Three cases of bone metastases in patients with gastrointestinal stromal tumors. Rare Tumors (2011) 1.12
Epithelial and mesenchymal tumor compartments exhibit in vivo complementary patterns of vascular perfusion and glucose metabolism. Neoplasia (2007) 1.12
Pulmonary artery intimal sarcoma. Problems in the differential diagnosis. Radiol Med (2013) 1.11
A novel model of CCl4-induced cirrhosis with ascites in the mouse. J Hepatol (2009) 1.10
11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. World J Surg Oncol (2007) 1.09
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. Clin Cancer Res (2010) 1.09
68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun (2009) 1.09
68Ga-DOTA-NOC PET/CT detects somatostatin receptors expression in von hippel-lindau cerebellar disease. Clin Nucl Med (2011) 1.08
11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. Eur J Nucl Med Mol Imaging (2013) 1.07
Biopsy-proved idiopathic pulmonary fibrosis: spectrum of nondiagnostic thin-section CT diagnoses. Radiology (2010) 1.06
Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. Nucl Med Commun (2005) 1.06
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer (2008) 1.05
Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy. Clin Cancer Res (2011) 1.05
PET/CT imaging in different types of lung cancer: an overview. Eur J Radiol (2011) 1.04
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. Cancer (2010) 1.04
The presence of emphysema further impairs physiologic function in patients with idiopathic pulmonary fibrosis. Respir Care (2006) 1.03
Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations. Cancer Treat Rev (2012) 1.03
Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging (2006) 1.02
Choline PET/CT for prostate cancer: main clinical applications. Eur J Radiol (2010) 1.02
Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med (2010) 1.02
Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer. Biomed Pharmacother (2006) 1.01
Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. AJR Am J Roentgenol (2006) 1.00
Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging (2008) 0.99
Benign metastasizing leiomyoma of the lung: PET findings. J Thorac Imaging (2009) 0.98
18F-FDG PET in malignant lymphoma: significance of positive findings. Eur J Nucl Med Mol Imaging (2005) 0.98
Role of ¹⁸F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer. Eur J Nucl Med Mol Imaging (2013) 0.98
The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab. Gastric Cancer (2007) 0.98
FDG PET/CT is useful for the interim evaluation of response to therapy in patients affected by haematogenous spondylodiscitis. Eur J Nucl Med Mol Imaging (2012) 0.98